The New Era of Therapeutic Radiopharmaceuticals

Marvin Burns

DOE/NCI Joint Workshop
June 17, 2002

Diagnostic-Therapeutic Analogs

- Low energy imaging agents employing traditional isotopes, such as technetium or indium, bound to a specific antibody or peptide

- High-energy therapeutic isotopes bound to the same antibody or peptide with affinity for the targeted tissue

New Radiotherapeutic Agents

Product	Indication	Radioisotope	Company
Zevalin	Non-Hodgkins Lymphoma	Yttrium-90	IDEC
Bexxar	Non-Hodgkins Lymphoma	Iodine–131	Corixa
Lympho-Cide	Non-Hodgkins Lymphoma	Yttrium-90 or I-131	Immunomedics
Oncolym	Non-Hodgkins Lymphoma	Iodine-131	Peregrine Pharm.
Pretargeted Anti CD-20 Agent	Non-Hodgkins Lymphoma	Yttrium-90	NeoRx
NeoTide	Lung Cancer	Rhenium-188	Berlex
CEA-Cide	Colorectal Cancer	Yttrium-90	Immunomedics
STR Agent	Bone Cancer/Myeloma	Holmium-166	NeoRx
SomatoTher	Endocrine Tumors	Indium-111	LSU University
OctreoTher	Endocrine Tumors	Leutitium 177, Indium-111	Novartis
Cotara	Brain Cancer	Iodine-131	Peregrine

FIGURE 1. HISTORIC AND FORECAST SALES GROWTH OF THERAPEUTIC RADIOPHARMACEUTICALS FROM 1996-2007



FIGURE 2. FORECAST SALES OF TARGETED THERAPEUTIC RADIOPHARMACEUTICALS BY DISEASE TYPE FROM 2001-2007



FIGURE 3. COMPARATIVE SALES GROWTH OF DIAGNOSTIC AND THERAPEUTIC RADIOPHARMACEUTICAL SALES FROM 1996-2007